Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

NCT07020247 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

184

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Rectal Cancer (LARC)
Immunotherapy
Radiotherapy
Total Neoadjuvant Therapy
Anal Function Preservation

Interventions

DRUG: Anti-PD-1 antibody drug named Serplulimab
RADIATION: Radiotherapy
DRUG: Chemotherapy

Sponsor

West China Hospital